Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.76 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.76 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.54 |
| ▸ | NOD1 | Q9Y239 | 10/20 | 0.45 |
| ▸ | FNTA | P49354 | 2/20 | 0.41 |
| ▸ | FNTB | P49356 | 2/20 | 0.41 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10797351 | 1.00 | PTGS1 (0.76) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL9817253 | 1.00 | PTGS1 (0.76) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL19293565 | 0.91 | PTGS1 (0.63) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL5934999 | 0.90 | PTGS1 (0.76) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL2153081 | 0.90 | PTGS1 (0.76) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL6660255 | 0.90 | PTGS1 (0.61) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL10490002 | 0.89 | PTGS1 (0.71) | PTGS1GSTK1GLO1NOD1FNTA | |
| Glutathione Ethyl Ester SCHEMBL7530345 | 0.89 | PTGS1 (0.71) | PTGS1GSTK1GLO1NOD1 | |
| SCHEMBL13238890 | 0.89 | PTGS1 (0.71) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL2015568 | 0.89 | PTGS1 (0.71) | PTGS1GSTK1GLO1NOD1FNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170002393-A1 | COMPOSITIONS AND METHODS FOR ANTIBODY PRODUCTION | IMMUNOGEN, INC. (US) | 2017-01-05 | — | — | US | claimed |
| EP-3077522-A1 | COMPOSITIONS AND METHODS FOR ANTIBODY PRODUCTION | Immunogen, Inc. (US) | 2016-10-12 | — | — | EP | claimed |
| US-9204996-B2 | Presbyopia treatment by lens alteration | ENCORE HEALTH, LLC (US) | 2015-12-08 | — | — | US | claimed |
| WO-2015085003-A1 | COMPOSITIONS AND METHODS FOR ANTIBODY PRODUCTION | IMMUNOGEN, INC. (US) | 2015-06-11 | — | — | WO | claimed |
| US-20140336562-A1 | Presbyopia Treatment by Lens Alteration | ENCORE HEALTH, LLC (US) | 2014-11-13 | — | — | US | claimed |
| US-8747829-B2 | Presbyopia treatment by lens alteration of disulfide bonds and reduction | ENCORE HEALTH, LLC (US) | 2014-06-10 | — | — | US | claimed |
| US-20110135622-A1 | Presbyopia Treatment by Lens Alteration | ENCORE HEALTH, LLC (US) | 2011-06-09 | — | — | US | claimed |
| EP-1808158-A2 | Presbyopia treatment by lens alteration | Newlens, LLC (US) | 2007-07-18 | — | — | EP | claimed |
| EP-0784471-B1 | MULTI-FACETED METHOD TO REPRESS REPRODUCTION OF LATENT VIRUSES IN HUMANS AND ANIMALS | HIV DIAGNOSTICS INC (US) | 2005-06-08 | — | — | EP | claimed |
| US-20050101677-A1 | Prophylaxis and/or reversing presbyopia by applying localized energy to area to be treated and administering biologically acceptable chemical substance capable of breaking chemical bonds such as disulfide bonds between cortical lens fibers | NEWLENS, LLC | 2005-05-12 | — | — | US | claimed |
| US-20020002136-A1 | Salts of glutathione | HEBERT ROLLAND F (US) | 2002-01-03 | — | — | US | claimed |
| US-5846961-A | Multi-faceted method to repress reproduction of latent viruses in humans and animals | HIV DIAGNOSTICS, INC. (US) | 1998-12-08 | — | — | US | claimed |
| EP-0784471-A4 | MULTI-FACETED METHOD TO REPRESS REPRODUCTION OF LATENT VIRUSES IN HUMANS AND ANIMALS | DYKE KNOX VAN (US) | 1997-11-19 | — | — | EP | claimed |
| US-5686436-A | SUPPRESSING HUMAN IMMUNODEFICIENCY VIRUS, FELINE IMMUNODEFICIENCY VIRUS, FELINE LEUKEMIA VIRUS | HIV DIAGNOSTICS, INC. (US) | 1997-11-11 | — | — | US | claimed |
| EP-0623342-B1 | Use of an alkyl ester of glutathione in a cosmetic or dermatological composition for the topical treatment of skin ageing | OREAL (FR) | 1997-09-17 | — | — | EP | claimed |
| EP-0784471-A2 | MULTI-FACETED METHOD TO REPRESS REPRODUCTION OF LATENT VIRUSES IN HUMANS AND ANIMALS | Van Dyke, Knox (US) | 1997-07-23 | — | — | EP | claimed |
| US-5516507-A | COMPOUNDS FOR TREATMENT OF AGING OF SKIN | L'OREAL (FR) | 1996-05-14 | — | — | US | claimed |
| WO-1996010402-A1 | MULTI-FACETED METHOD TO REPRESS REPRODUCTION OF LATENT VIRUSES IN HUMANS AND ANIMALS | DYKE KNOX VAN (US) | 1996-04-11 | — | — | WO | claimed |
| WO-1994017799-A1 | METHOD FOR TREATING INFERTILITY | FREE RADICAL SCIENCES, INC. (US) | 1994-08-18 | — | — | WO | claimed |
| US-4879370-A | ALKYL ESTER TO INCREASE CELLULAR LEVELS | CORNELL RESEARCH FOUNDATION, INC. (US) | 1989-11-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135622-A1 | Presbyopia Treatment by Lens Alteration | CRYAB, CRYAA, MYOC | PTGS1 1016/4885GSTK1 1599/4885GLO1 1174/4885 |
| US-20170002393-A1 | COMPOSITIONS AND METHODS FOR ANTIBODY PRODUCTION | TXNRD1, P4HB, CYBB | PTGS1 1016/4885GSTK1 270/4885GLO1 540/4885 |
| US-20050101677-A1 | Prophylaxis and/or reversing presbyopia by applying localized energy to area to be treated and administering biologically acceptable chemical substance capable of breaking chemical bonds such as disulfide bonds between cortical lens fibers | CRYAB, CRYAA, PSEN2 | PTGS1 228/4885GSTK1 50/4885GLO1 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.